Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of outcomes in relapsed/refractory LPL/Waldenström txd with venetoclax -> ORR and MRR 70% and 63%; median and 2-year PFS 28.5 months and 57%; median and 2-year OS not reached and 82%; prior BTK inhibitor only factor associated with PFS.”

“Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis”

Authors: Y. Sawalha, S. Sarosiek, R. L. Welkie, S. Seif, S. Thapa, P. Kapoor, A. Grajales-Cruz, K. H. Shain, S. K. Thomas, J. J. Castillo et al.

Myeloma Paper of the Day, April 16th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.